Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PRNP | P04156 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13159337 | 0.87 | EPHX1 (0.36) | EPHX1TACR1LMNAPRNPRXFP1 | |
| SCHEMBL13159596 | 0.84 | MEN1 (0.39) | L3MBTL1 | |
| SCHEMBL13159411 | 0.84 | EPHX1 (0.34) | EPHX1TACR1LMNAPRNPRXFP1 | |
| SCHEMBL13159570 | 0.82 | KDM4E (0.41) | LMNACYP1A2CYP2C19L3MBTL1 | |
| SCHEMBL13159457 | 0.80 | EPHX1 (0.37) | EPHX1TACR1LMNAPRNPRXFP1 | |
| SCHEMBL13159594 | 0.80 | GPR84 (0.35) | CYP1A2CYP2D6CYP2C19L3MBTL1 | |
| SCHEMBL8065282 | 0.78 | THRB (0.46) | EPHX1CYP1A2CYP2C19L3MBTL1HTR2A | |
| SCHEMBL13159602 | 0.78 | CASR (0.31) | — | |
| SCHEMBL13159552 | 0.77 | KDM4E (0.41) | — | |
| SCHEMBL13159583 | 0.77 | KDM4E (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8808960-B2 | Compound and chemically amplified positive resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8808960-B2 | Compound and chemically amplified positive resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20100233628-A1 | COMPOUND AND CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100233628-A1 | COMPOUND AND CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233628-A1 | COMPOUND AND CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION | HRH3, C9, H1-2 | EPHX1 3913/4885TACR1 544/4885LMNA 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.